drug_type
RELEVANT_DRUG
intervention_type
Biological; autologous CAR T-cell therapy
drug_description
An autologous, gene-modified anti-CD19 chimeric antigen receptor (CAR) T-cell therapy administered as a single IV infusion. Patient T cells are engineered to express a CD19-directed CAR that, upon target engagement, activates cytotoxic effector functions to deplete CD19+ B-lineage cells and plasmablasts, aiming to reduce pathogenic B-cell activity and CNS inflammation in progressive multiple sclerosis.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified to express a CD19-directed chimeric antigen receptor. Upon binding CD19 on B-lineage cells (including naive/memory B cells and plasmablasts), the CAR triggers T-cell activation and cytotoxic effector functions (e.g., perforin/granzyme), leading to targeted depletion of CD19+ cells. This reduces pathogenic B-cell activity and associated CNS inflammation implicated in progressive multiple sclerosis.
drug_name
rapcabtagene autoleucel (YTB323)
nct_id_drug_ref
NCT06675864